G Leonard Baker, Jr. Purchases 100,000 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $34.64 on Friday. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33. The firm has a market cap of $3.68 billion, a P/E ratio of 42.24 and a beta of 0.29. The stock has a fifty day moving average price of $37.46 and a two-hundred day moving average price of $61.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.26 EPS. Research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CORT. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a report on Wednesday, December 31st. Finally, Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $77.17.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after acquiring an additional 2,444 shares in the last quarter. Amundi purchased a new stake in shares of Corcept Therapeutics in the first quarter worth approximately $450,000. NewEdge Advisors LLC acquired a new stake in shares of Corcept Therapeutics during the first quarter worth approximately $518,000. Police & Firemen s Retirement System of New Jersey grew its position in Corcept Therapeutics by 102.3% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 35,739 shares of the biotechnology company’s stock valued at $2,623,000 after purchasing an additional 18,074 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Corcept Therapeutics by 8.6% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 24,231 shares of the biotechnology company’s stock valued at $1,779,000 after purchasing an additional 1,916 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.